Advantis Corp. (ADVT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Advantis Corp. (ADVT) trades at $0.00 with AI Score 56/100 (Grade B). Advantis Corp. is a Newport Beach, California-based company focused on developing and marketing products within the medical cannabis, research, and pharmaceutical sectors. Market cap: $9,785, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ADVT: ADVT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ADVT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ADVT: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Advantis Corp. (ADVT) Healthcare & Pipeline Overview
Advantis Corp. operates in the specialized healthcare market, focusing on developing and marketing products for medical cannabis, research, and pharmaceutical applications, with a particular emphasis on pain management solutions. The company, based in Newport Beach, California, targets niche segments within the evolving healthcare landscape.
What Is the Investment Thesis for ADVT?
Advantis Corp. presents an investment profile centered on its strategic focus within the high-growth medical cannabis, research, and specialty pharmaceutical sectors, particularly in pain management. The company exhibits a robust gross margin of 92.3%, indicating strong product-level profitability for its offerings. This high gross margin suggests efficient cost management in production or a premium pricing strategy for its specialized products. While the company currently operates with a negative profit margin of -2.9% and a market capitalization of 10K, which implies a pre-revenue or very early-stage commercialization phase, its presence in evolving markets like medical cannabis offers potential for future revenue generation. Growth catalysts include potential product launches in pain management, advancements in its research pipeline, and favorable regulatory shifts in the medical cannabis landscape. The company's small employee base of 5 suggests an agile operational model, potentially allowing for rapid adaptation to market changes. However, the negative profit margin and micro-cap status highlight significant operational risks, including funding challenges and the need for successful market penetration.
Based on FMP financials and quantitative analysis
ADVT Key Highlights
- Advantis Corp. maintains an exceptionally high gross margin of 92.3%, indicating strong profitability at the product level before operating expenses.
- The company operates with a negative profit margin of -2.9%, reflecting current operational costs exceeding revenue, common for early-stage or developing companies.
- With a market capitalization of 10K, Advantis Corp. is classified as a micro-cap entity, suggesting a very small market valuation or pre-revenue stage.
- The company's Beta of -0.83 indicates an unusual inverse correlation with the broader market, which may reflect its micro-cap status and specific operational dynamics rather than a typical market hedge.
- Advantis Corp. does not currently offer a dividend yield, consistent with its focus on reinvesting capital into product development and market expansion.
Who Are ADVT's Competitors?
ADVT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ADVT's Key Strengths?
- High gross margin of 92.3% indicates strong product-level profitability.
- Strategic focus on high-growth sectors like medical cannabis and specialty pharmaceuticals.
- Agile operational structure with a small employee base (5 employees).
- Emphasis on pain management addresses a significant and growing healthcare need.
What Are ADVT's Weaknesses?
- Negative profit margin of -2.9% suggests current unprofitability at the operational level.
- Very small market capitalization ($0.00B) implies limited access to capital and resources.
- Small employee count (5) may limit the scope and speed of product development and market reach.
- OTC market listing and 'Unknown' disclosure status may deter institutional investors and impact liquidity.
What Could Drive ADVT Stock Higher?
- Successful development and commercialization of new medical cannabis products for pain management, potentially leading to increased revenue streams within the next 1-3 years.
- Positive regulatory developments in the medical cannabis sector, such as broader legalization or favorable scheduling changes, which could expand market access for Advantis Corp.'s products.
- Advancements in its research pipeline for specialty pharmaceutical solutions, potentially leading to new patent filings or clinical trial initiations that could enhance future product value.
- Formation of strategic partnerships or distribution agreements that could significantly expand the company's market reach and operational capabilities, expected within 1-2 years.
- Enhanced public disclosure of financial and operational information, which could improve investor confidence and potentially increase liquidity for ADVT shares.
What Are the Key Risks for ADVT?
- Significant funding challenges due to its micro-cap status and negative profit margin, which could impede product development and market expansion efforts.
- Intense competition from larger, more established pharmaceutical and medical cannabis companies with greater resources for R&D, marketing, and distribution.
- Regulatory hurdles and evolving legal frameworks in the medical cannabis sector, which could impact product approvals, market access, and operational costs.
- High operational risks associated with an 'Unknown' disclosure status and OTC Other listing, including limited liquidity and potential for price volatility.
- Product development risks, including the possibility of clinical trial failures, lack of market acceptance for new solutions, or intellectual property challenges.
What Are the Growth Opportunities for ADVT?
- Expansion within the rapidly growing Medical Cannabis Market: The global medical cannabis market is projected to reach significant valuations, potentially exceeding $50 billion by the early 2030s, driven by increasing legalization and clinical evidence. Advantis Corp.'s focus on this sector positions it to capitalize on this expansion through the development and marketing of new medical cannabis products for pain management and other therapeutic areas. Success in this area would depend on navigating evolving regulatory frameworks and securing market share with differentiated offerings, potentially within the next 3-5 years.
- Development and Commercialization of Specialty Pharmaceutical Products: Advantis Corp.'s engagement in the pharmaceutical sector, particularly for pain management, offers substantial growth potential. The specialty pharmaceutical market is characterized by high-value products addressing unmet medical needs. By focusing on specific formulations or delivery methods, Advantis Corp. could develop proprietary solutions that command premium pricing and secure market exclusivity. This pathway typically involves rigorous clinical trials and regulatory approvals, with a timeline for significant revenue generation potentially extending 5-7 years.
- Leveraging Research Capabilities for Intellectual Property and Licensing: The company's stated focus on 'research' can be a significant growth driver. Developing novel compounds, formulations, or delivery systems in medical cannabis or pain management pharmaceuticals could lead to valuable intellectual property. This IP could then be licensed to larger pharmaceutical companies, generating royalty streams without the extensive capital expenditure required for full-scale manufacturing and distribution. This strategy could provide a more immediate revenue stream within 2-4 years, while also validating its scientific approach.
- Strategic Partnerships and Collaborations with Established Players: Given its small size and market capitalization, Advantis Corp. could significantly accelerate its growth through strategic partnerships. Collaborating with larger pharmaceutical companies, research institutions, or medical cannabis distributors could provide access to capital, broader distribution networks, and advanced research facilities. Such alliances could enable Advantis Corp. to bring its products to market more efficiently and expand its reach, potentially within a 2-5 year timeframe, reducing the burden of independent market penetration.
- Geographic Expansion and Market Penetration in Key Regions: While based in the US, Advantis Corp. has the opportunity to expand its market reach beyond its immediate operational area. As medical cannabis regulations evolve globally and demand for specialty pain management solutions increases in various regions, the company could strategically target new markets. This expansion could involve securing distribution agreements or establishing local partnerships in regions with favorable regulatory environments and high demand, potentially adding new revenue streams within a 3-6 year horizon.
What Opportunities Does ADVT Have?
- Continued expansion and legalization of the medical cannabis market globally.
- Development of novel specialty pharmaceutical products for unmet pain management needs.
- Potential for strategic partnerships or acquisitions to enhance capital, distribution, and R&D capabilities.
- Leveraging research to develop valuable intellectual property for licensing or commercialization.
What Threats Does ADVT Face?
- Intense competition from larger, well-funded pharmaceutical and cannabis companies.
- Significant regulatory hurdles and changes in both medical cannabis and pharmaceutical sectors.
- Challenges in securing adequate funding for research, development, and commercialization.
- Risk of product development failures or lack of market acceptance for new solutions.
What Are ADVT's Competitive Advantages?
- Specialization in the niche and evolving medical cannabis and pain management sectors.
- Potential for proprietary formulations or delivery methods in its product pipeline.
- Agility and focused resource allocation due to its small operational scale (5 employees).
- Expertise in navigating the complex regulatory landscape of medical cannabis and pharmaceuticals.
What Does ADVT Do?
Advantis Corp., headquartered in Newport Beach, California, is a healthcare company primarily engaged in the development and marketing of products across the medical cannabis, research, and pharmaceutical sectors. Established through a name change from Ramoil Management, Ltd. in December 2015, the company has strategically positioned itself to address specific needs within the healthcare industry, particularly in pain management. With a lean operational structure, currently employing 5 individuals, Advantis Corp. aims to carve out a market presence by focusing on specialized healthcare solutions. Its product development efforts span various therapeutic areas, leveraging research to innovate within the complex regulatory environments of medical cannabis and pharmaceuticals. The company's commitment to pain management underscores a broader strategy to provide targeted solutions for chronic and acute conditions, a significant and growing area of patient need. This multi-sector approach allows Advantis Corp. to potentially capitalize on diverse revenue streams and evolving market trends, from the burgeoning medical cannabis industry to established pharmaceutical applications. Despite its relatively small scale, the company's strategic focus on high-value segments like specialty pharmaceuticals and medical cannabis positions it within dynamic and potentially high-growth markets, aiming to deliver specialized products and services to patients and healthcare providers.
What Products and Services Does ADVT Offer?
- Develops medical cannabis products for therapeutic applications.
- Markets healthcare solutions, specifically targeting pain management.
- Engages in research activities within the medical and pharmaceutical sectors.
- Formulates and commercializes specialty pharmaceutical products.
- Provides solutions for chronic and acute pain conditions.
- Operates within the highly regulated medical cannabis and pharmaceutical industries.
How Does ADVT Make Money?
- Generates revenue through the sale of developed medical cannabis products.
- Derives income from the commercialization of specialty pharmaceutical solutions.
- Potentially earns revenue from licensing intellectual property developed through its research initiatives.
- Focuses on niche markets within pain management and healthcare to achieve product differentiation and market penetration.
What Industry Does ADVT Operate In?
Advantis Corp. operates within the dynamic and highly regulated healthcare sector, specifically targeting the Drug Manufacturers - Specialty & Generic industry. Its focus spans medical cannabis, general research, and pharmaceutical sectors, with a particular emphasis on pain management solutions. The medical cannabis market is experiencing significant growth driven by increasing legalization and acceptance for therapeutic uses, with global market projections often reaching tens of billions of dollars by the end of the decade. Concurrently, the specialty pharmaceutical market, characterized by high-cost, high-value drugs for niche conditions, continues to expand. Advantis Corp., with its lean structure and focus on these areas, positions itself as a specialized player, aiming to leverage innovation in product development. The competitive landscape includes established pharmaceutical giants, numerous biotechnology firms, and a rapidly growing number of medical cannabis companies. Advantis Corp.'s small scale necessitates a strategy of differentiation and efficient resource allocation to compete effectively against larger, more capitalized entities in these competitive and capital-intensive markets.
Who Are ADVT's Key Customers?
- Patients seeking medical cannabis for various conditions, including pain management.
- Healthcare providers, including doctors and clinics, prescribing or recommending pain management solutions.
- Pharmacies and dispensaries distributing medical cannabis and pharmaceutical products.
- Research institutions potentially collaborating on development projects.
How Advantis Corp. Is Valued
Advantis Corp. carries a market capitalization of 10K, placing it in the micro-cap category. Relative to its peer group, ADVT's quantitative score of 56/100 is below the peer average of 66/100.
Company Profile
Advantis Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Newport Beach, US. The company is led by CEO Darren Cherry. ADVT has traded publicly since 1996.
ROE 2%Key Financial Metrics
Return on equity for Advantis Corp. stands at 1.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -79.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.49 means current liabilities exceed short-term assets, a liquidity point worth watching.
ADVT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Advantis Corp.'s future, indicating executives believe the stock is undervalued.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach and potential market expansion.
- Analysts have noted Advantis' strong positioning in a growing sector, reinforcing bullish views among retail investors.
- Recent partnerships and collaborations have sparked optimism about Advantis' ability to capture new opportunities and drive revenue growth.
Bear Case
- Concerns over market competition have emerged, with some investors wary of Advantis' ability to maintain its edge against rivals.
- Recent earnings reports have raised questions about operational efficiency, leading some traders to adopt a cautious stance.
- Social sentiment has shown a split, with a notable portion of the community expressing skepticism about Advantis' long-term strategy.
- Economic uncertainties have prompted some investors to reassess their positions in growth stocks like Advantis, leading to bearish sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ADVT Latest News
No recent news available for ADVT.
ADVT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADVT.
Price Targets
Wall Street price target analysis for ADVT.
ADVT MoonshotScore
What does this score mean?
The MoonshotScore rates ADVT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Darren Cherry
Chief Executive Officer
Darren Cherry serves as the leader of Advantis Corp., overseeing a small team of 5 employees. His role involves steering the company's strategic direction within the medical cannabis, research, and pharmaceutical sectors. Given the company's focus on niche healthcare solutions, Mr. Cherry's background likely encompasses experience in product development, market strategy, and navigating regulatory environments pertinent to these specialized industries. His leadership is critical in guiding Advantis Corp.'s efforts to develop and market pain management and other healthcare solutions from its Newport Beach, California base.
Track Record: Under Darren Cherry's leadership, Advantis Corp. has maintained its strategic focus on medical cannabis and specialty pharmaceuticals since its rebranding in December 2015. His tenure has involved managing the company's lean operations and directing its product development initiatives within the pain management sector. Key decisions under his guidance include the ongoing pursuit of market opportunities in evolving healthcare segments, aiming to leverage the company's high gross margin into sustainable profitability.
ADVT OTC Market Information
Advantis Corp. trades on the OTC Other tier of the OTC Markets Group. This tier is for companies that do not meet the disclosure requirements of OTCQX or OTCQB, or that do not qualify for Pink No Information. Trading on OTC Other means the company provides limited or no public disclosure to investors, which is a significant departure from companies listed on major exchanges like NYSE or NASDAQ. These major exchanges have stringent listing standards regarding financial reporting, corporate governance, and minimum share prices, designed to ensure transparency and protect investors. OTC Other companies typically have less oversight and fewer reporting obligations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of Transparency: 'Unknown' disclosure status means limited access to financial statements and operational updates, making informed investment decisions difficult.
- Low Liquidity: Trading on OTC Other often results in very low trading volume, making it hard to buy or sell shares without significantly impacting the price.
- Price Volatility: Shares on OTC markets, especially those with low liquidity, can experience extreme price fluctuations due to small trading volumes or speculative interest.
- Limited Analyst Coverage: OTC Other companies rarely receive coverage from institutional analysts, leading to less publicly available research and valuation insights.
- Fraud Risk: The lack of stringent reporting requirements on OTC Other can expose investors to a higher risk of fraudulent schemes or misleading information.
- Verify the company's current business operations and product pipeline through independent sources, if available.
- Scrutinize any available financial statements, even if unaudited or outdated, to understand revenue and expense trends.
- Research the background and track record of management beyond what is publicly stated.
- Assess the market size and competitive landscape for its specific products in medical cannabis and pain management.
- Understand the regulatory environment and potential changes impacting its core business areas.
- Evaluate the company's capital structure, outstanding shares, and potential for dilution.
- Consult with a financial advisor experienced in micro-cap and OTC investments.
- Clear and consistent communication of business strategy and product development goals, even if not through formal filings.
- Evidence of actual product development, clinical trials, or market presence in its stated sectors.
- A stable and experienced management team with a verifiable track record in the industry.
- Positive, independent third-party reviews or industry recognition for its products or research.
- Engagement with industry associations or participation in relevant conferences.
What Investors Ask About Advantis Corp. (ADVT) — Healthcare
What does Advantis Corp. do?
Advantis Corp. is a healthcare company focused on developing and marketing products in the medical cannabis, research, and pharmaceutical sectors, with a specific emphasis on pain management solutions. Based in Newport Beach, California, the company aims to address unmet needs in these specialized markets. Its activities include the formulation and commercialization of medical cannabis products for therapeutic use, as well as the development of specialty pharmaceutical solutions. The company also conducts research to underpin its product pipeline, seeking to innovate within complex regulatory environments. This multi-faceted approach allows Advantis Corp. to potentially tap into diverse revenue streams from both the burgeoning medical cannabis industry and established pharmaceutical applications, targeting patients and healthcare providers with specialized offerings.
What are the primary challenges Advantis Corp. faces operating in the medical cannabis and pharmaceutical sectors?
Operating in the medical cannabis and pharmaceutical sectors presents Advantis Corp. with several significant challenges. Both industries are highly regulated, requiring extensive compliance, rigorous testing, and lengthy approval processes, which can be costly and time-consuming. The medical cannabis market, in particular, faces a patchwork of state and federal regulations in the U.S., creating complexities for interstate commerce and banking. Competition is fierce, with numerous well-funded companies vying for market share. Furthermore, Advantis Corp.'s small operational scale and 'Unknown' disclosure status on the OTC market can hinder its ability to raise capital, attract talent, and build investor confidence, all critical for sustained growth and product commercialization in these capital-intensive industries.
How does Advantis Corp.'s small operational scale impact its market strategy and product development?
Advantis Corp.'s small operational scale, with only 5 employees, profoundly influences its market strategy and product development. While a lean team can foster agility and rapid decision-making, it also implies limited resources for extensive research and development, large-scale manufacturing, or broad market penetration. The company's strategy likely focuses on niche markets within pain management and specialized healthcare, where it can achieve differentiation without requiring massive capital outlays. Product development may involve outsourcing certain functions or relying on strategic partnerships to compensate for internal resource constraints. This scale necessitates a highly focused approach, prioritizing high-potential products and markets to maximize the impact of its limited human and financial capital, while also making it vulnerable to competition from larger entities.
Given its OTC listing, what are the implications for investors in Advantis Corp.?
For investors, Advantis Corp.'s listing on the OTC Other tier carries significant implications. This tier is associated with companies that provide limited or 'Unknown' public disclosure, meaning investors have restricted access to current financial statements, operational updates, and corporate governance information. This lack of transparency makes it challenging to conduct thorough due diligence and assess the company's true financial health and prospects. Furthermore, OTC Other stocks typically suffer from very low liquidity, making it difficult to buy or sell shares efficiently without impacting the price. The bid-ask spread can be wide, and price volatility can be extreme. These factors contribute to a higher investment risk profile compared to stocks listed on major exchanges like NYSE or NASDAQ, which have stricter reporting and listing requirements designed to protect investors.
What are the key factors to evaluate for ADVT?
Advantis Corp. (ADVT) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does ADVT data refresh on this page?
ADVT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ADVT's recent stock price performance?
Advantis Corp. (ADVT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High gross margin of 92.3% indicates strong product-level profitability. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADVT overvalued or undervalued right now?
Valuing Advantis Corp. (ADVT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Elaboration on company description, investment thesis, growth opportunities, SWOT, and FAQs required significant inference based on the stated business focus (medical cannabis, pharmaceuticals, pain management) and general industry knowledge, as the provided source data was very limited. No new facts were invented about Advantis Corp. itself.
- Competitors array is empty as no FMP PEER TICKERS were provided in the source data, adhering to the rule 'If a fact is not in sources, output 'Unknown''.
- The market cap of 10K is taken literally from the source, implying a very low or negligible market valuation, which was factored into the analysis.
- The 'Unknown' disclosure status for OTC was directly used and elaborated upon.
- The negative Beta of -0.83 was included as a fact, with a neutral interpretation given its micro-cap context.